Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib. Pemigatinib is an oral targeted anticancer medicine that inhibits fibroblast growth factor receptors 1, 2 and 3. It is used in selected cancer treatment settings involving specific FGFR genetic abnormalities. The manufacturer and regulatory status of the specific Pemitinib-branded product require independent confirmation.
The generic medicine identified for Pemitinib is pemigatinib. Pemigatinib belongs to the FGFR inhibitor class and works by blocking selected receptor tyrosine kinase proteins involved in cellular signaling. Pemigatinib identifies the active pharmaceutical ingredient, while Pemitinib is the product name used on this website.
Pemigatinib is a targeted anticancer medicine classified as a small-molecule kinase inhibitor. More specifically, it is a selective inhibitor of FGFR1, FGFR2 and FGFR3. It works by interfering with abnormal signaling pathways that may contribute to cancer-cell growth and survival. It is different from conventional chemotherapy because it targets particular molecular proteins.
Under applicable regulatory labeling, pemigatinib has recognized uses in selected adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an eligible FGFR2 fusion or rearrangement. U.S. prescribing information also includes adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement. Eligibility depends on the exact diagnosis, molecular test results and local regulatory requirements.
No. Pemigatinib is not a general treatment for all liver cancers. Its cholangiocarcinoma indication applies to selected patients whose tumors contain a qualifying FGFR2 fusion or rearrangement and meet the relevant previous-treatment and disease-status requirements. Other liver cancers, including hepatocellular carcinoma, should not automatically be considered suitable for pemigatinib. A specialist must confirm the diagnosis and molecular findings.
Pemigatinib blocks the kinase activity of FGFR1, FGFR2 and FGFR3. These proteins normally participate in signaling processes that regulate cell growth, survival and development. Certain genetic abnormalities can cause FGFR signaling to become abnormally active in cancer cells. By inhibiting selected FGFR proteins, pemigatinib interferes with these abnormal signals and provides a targeted treatment approach.
Under U.S. reference-product prescribing information, the usual dose for eligible adults with FGFR2-altered cholangiocarcinoma is 13.5 mg once daily for 14 consecutive days, followed by seven days without treatment. For eligible adults with FGFR1-rearranged myeloid/lymphoid neoplasms, the labeled U.S. regimen is 13.5 mg once daily continuously. The correct schedule depends on the specific indication and must be prescribed by a specialist.
For the U.S. labeled cholangiocarcinoma regimen, one cycle lasts 21 days. Patients take pemigatinib for the first 14 days and then have a seven-day treatment break. This cycle is repeated according to the specialist's treatment plan. The continuous daily regimen for FGFR1-rearranged myeloid/lymphoid neoplasms is different and does not follow this routine 14-days-on, seven-days-off schedule.
The reference-product instructions allow pemigatinib to be taken with or without food. Patients do not generally need to take the medicine at a particular time relative to meals. It is important to follow the product's administration instructions and maintain the treatment schedule prescribed by the healthcare professional.
According to U.S. reference-product instructions, a missed dose may be taken if the next scheduled dose is at least four hours away. If the next dose is less than four hours away, the missed dose should be skipped. The patient should then continue with the next scheduled dose. Do not take an extra tablet to make up for a missed dose.
If vomiting occurs after a dose, patients should not take an additional tablet to replace the dose. They should resume treatment at the next scheduled dosing time. Taking another dose may lead to unintended additional exposure. Persistent vomiting or difficulty maintaining treatment should be discussed with the healthcare professional.
Commonly reported adverse reactions vary by treatment indication. They may include hyperphosphatemia, hair loss, diarrhea, nail disorders, fatigue, nausea, constipation, stomatitis, dry eyes, dry mouth, reduced appetite, vomiting and skin changes. Not every patient experiences these effects, and their severity may differ. Patients should report persistent or troublesome symptoms to their treating specialist.
Pemigatinib inhibits FGFR signaling, which can affect the body's normal regulation of phosphate. This may cause hyperphosphatemia, meaning an increased concentration of phosphate in the blood. High phosphate levels can sometimes contribute to calcium-phosphate deposits in soft tissues. Regular blood testing helps healthcare professionals identify and manage this adverse reaction.
Yes. Pemigatinib can cause ocular adverse reactions, including retinal pigment epithelial detachment. Patients should have appropriate eye examinations before treatment and during therapy. New blurred vision, visual floaters, flashes of light or other changes in eyesight should be reported promptly. Patients should not wait until their next routine appointment if visual symptoms develop.
Hair loss, or alopecia, is among the adverse reactions reported with pemigatinib. The extent of hair loss can vary between patients. Some people may experience noticeable thinning, while others may have less significant changes. Patients concerned about hair loss should discuss symptom management and supportive care with their healthcare team.
Yes. Pemigatinib can interact with medicines that affect CYP3A enzymes. Strong or moderate CYP3A inducers may reduce pemigatinib exposure, while strong or moderate CYP3A inhibitors may increase exposure. These changes can affect treatment safety or effectiveness. Patients should provide their healthcare professionals with a complete list of prescription medicines, over-the-counter products, vitamins and herbal supplements.
Pemigatinib should only be used when prescribed for an appropriate medical indication. Patients who do not have the required molecular abnormality or who do not meet the relevant treatment criteria may not be suitable candidates. A specialist must also assess pregnancy considerations, other medical conditions, potential drug interactions and the patient's ability to undergo recommended monitoring. The U.S. reference-product labeling does not list a formal contraindication, but this does not mean the medicine is suitable for everyone.
Pemigatinib is an anticancer medicine, but it is classified as a targeted therapy rather than conventional cytotoxic chemotherapy. It acts on selected FGFR proteins involved in cellular signaling. Conventional chemotherapy medicines generally affect rapidly dividing cells through different mechanisms. Both approaches are used in cancer care, but their mechanisms, indications and adverse-effect profiles can differ.
Yes, molecular testing is important for determining eligibility for the relevant pemigatinib indications. For cholangiocarcinoma, an eligible FGFR2 fusion or rearrangement must be identified. For the U.S. FGFR1-rearranged myeloid/lymphoid neoplasm indication, the relevant FGFR1 rearrangement must be established. A specialist must interpret the results and determine whether they meet the applicable prescribing requirements.
Pemitinib and PEMAZYRE are names associated with products identified as containing pemigatinib, but they should not automatically be treated as identical pharmaceutical products. PEMAZYRE is the established reference brand. The specific manufacturer, authorization, formulation, packaging and regulatory status of Pemitinib must be verified from its own official documentation.
Pemigatinib may cause fetal harm based on its mechanism of action and nonclinical findings. Pregnancy status and reproductive risks should be discussed with the treating specialist before treatment. U.S. reference-product labeling advises effective contraception for females of reproductive potential during treatment and for one week after the final dose. Specific recommendations for male patients and partners should also be discussed with the healthcare professional.
Patients should follow the storage instructions printed on the actual medicine packaging and supplied product information. Keep prescription medicines in their original packaging when appropriate, protect them from unsuitable environmental conditions and store them safely away from children. Do not use tablets beyond their expiry date or tablets with damaged or questionable packaging. Product-specific storage conditions should be confirmed from the supplied instructions.
Yes. Dose reductions may be necessary when a patient experiences certain adverse reactions or has specific medical conditions. The U.S. reference-product prescribing information includes lower dose levels of 9 mg and 4.5 mg for appropriate dose modifications. The reason for adjustment, treatment indication and patient's clinical status determine the correct approach. Patients must never reduce the dose independently.
Under U.S. reference-product prescribing information, patients should have an eye examination, including OCT, before beginning treatment. Follow-up examinations are recommended every two months during the first six months and every three months afterward while receiving treatment. Additional examinations may be needed if symptoms develop. The treating specialist may adjust monitoring according to the patient's clinical circumstances.
No. Pemitinib.com is an educational website and does not provide medical prescriptions, diagnosis or individualized treatment recommendations. Pemigatinib is a prescription anticancer medicine that requires professional supervision. Patients should consult a qualified oncologist or hematologist before starting treatment, changing a dose or stopping therapy.